DR Congo authorises trial of experimental Ebola vaccine

Image
AFP Kinshasa
Last Updated : May 29 2017 | 7:42 PM IST
The Democratic Republic of Congo has approved using an experimental Ebola vaccine to combat an outbreak of the virus in the northeast, the government said today.
"The DRC accepts the use of vaccines against the Ebola virus," a source in the health ministry told AFP, adding that the government concluded it had no objections to the tests being conducted in the country.
"We're waiting for an operational plan from our partners which will determine what steps need to be taken, in which geographic areas we could vaccinate," the source added, on condition of anonymity.
A definitive decision on how the vaccine would be deployed will be released in 24 hours, the source said.
There is no licensed vaccine for the Ebola virus, but the World Health Organization said this month that a promising candidate vaccine exists and could be deployed within a matter of days if the DR Congo government gave its approval.
On May 12, DR Congo declared an outbreak of the highly contagious disease, the eighth to date in a sprawling country five times the size of France.
A week later, researchers in the United States said they had found antibodies that could be used to neutralise the three main strains of Ebola.
So far, two cases of the virus have been confirmed in a laboratory while 18 others are suspected in the remote Bas- Uele province, an equatorial forest zone near the Central African Republic.
Three of those people have died, including the first known case, a 39-year-old man who died on the way to hospital in Likati on April 22, suffering from fever, vomiting and bleeding symptoms.
It is the first outbreak of Ebola, which spreads by contact with bodily fluids, since the west Africa epidemic that ended in January last year after killing more than 11,300 people and sickening nearly 29,000.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 29 2017 | 7:42 PM IST

Next Story